Hicks Jennifer, Klumpp-Thomas Carleen, Kalish Heather, Shunmugavel Anandakumar, Mehalko Jennifer, Denson John-Paul, Snead Kelly R, Drew Matthew, Corbett Kizzmekia S, Graham Barney S, Hall Matthew D, Memoli Matthew J, Esposito Dominic, Sadtler Kaitlyn
Trans-NIH Shared Resource on Biomedical Engineering and Physical Science, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD, 20894, USA.
Section on Immuno-Engineering, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD, 20892, USA.
J Clin Immunol. 2021 Jul;41(5):906-913. doi: 10.1007/s10875-021-00997-6. Epub 2021 Mar 16.
In order to properly understand the spread of SARS-CoV-2 infection and development of humoral immunity, researchers have evaluated the presence of serum antibodies of people worldwide experiencing the pandemic. These studies rely on the use of recombinant proteins from the viral genome in order to identify serum antibodies that recognize SARS-CoV-2 epitopes. Here, we discuss the cross-reactivity potential of SARS-CoV-2 antibodies with the full spike proteins of four other betacoronaviruses that cause disease in humans, MERS-CoV, SARS-CoV, HCoV-OC43, and HCoV-HKU1. Using enzyme-linked immunosorbent assays (ELISAs), we detected the potential cross-reactivity of antibodies against SARS-CoV-2 towards the four other coronaviruses, with the strongest cross-recognition between SARS-CoV-2 and SARS /MERS-CoV antibodies, as expected based on sequence homology of their respective spike proteins. Further analysis of cross-reactivity could provide informative data that could lead to intelligently designed pan-coronavirus therapeutics or vaccines.
为了正确理解严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染的传播和体液免疫的发展，研究人员评估了全球经历该大流行的人群血清抗体的存在情况。这些研究依赖于使用病毒基因组的重组蛋白来识别识别SARS-CoV-2表位的血清抗体。在此，我们讨论了SARS-CoV-2抗体与另外四种可导致人类疾病的β冠状病毒（中东呼吸综合征冠状病毒、严重急性呼吸综合征冠状病毒、人冠状病毒OC43和人冠状病毒HKU1）的全长刺突蛋白的交叉反应可能性。使用酶联免疫吸附测定（ELISA），我们检测了抗SARS-CoV-2抗体对其他四种冠状病毒的潜在交叉反应，正如基于它们各自刺突蛋白的序列同源性所预期的那样，SARS-CoV-2与SARS/中东呼吸综合征冠状病毒抗体之间的交叉识别最强。对交叉反应的进一步分析可以提供有益的数据，从而有助于设计出智能的泛冠状病毒疗法或疫苗。
